CN117045762B - Compound traditional Chinese medicine for treating gastric precancerous lesions and preparation method - Google Patents
Compound traditional Chinese medicine for treating gastric precancerous lesions and preparation method Download PDFInfo
- Publication number
- CN117045762B CN117045762B CN202311237212.7A CN202311237212A CN117045762B CN 117045762 B CN117045762 B CN 117045762B CN 202311237212 A CN202311237212 A CN 202311237212A CN 117045762 B CN117045762 B CN 117045762B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- pill
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 103
- 230000002496 gastric effect Effects 0.000 title claims abstract description 33
- 150000001875 compounds Chemical class 0.000 title claims abstract description 31
- 230000003902 lesion Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 29
- 239000006187 pill Substances 0.000 claims abstract description 73
- 241000218176 Corydalis Species 0.000 claims abstract description 13
- 241001673966 Magnolia officinalis Species 0.000 claims abstract description 13
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 11
- 235000005412 red sage Nutrition 0.000 claims abstract description 11
- 241000258920 Chilopoda Species 0.000 claims abstract description 10
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 9
- 241000132012 Atractylodes Species 0.000 claims abstract description 8
- 210000003038 endothelium Anatomy 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 63
- 239000000843 powder Substances 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 17
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 16
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 238000005498 polishing Methods 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 7
- 235000012907 honey Nutrition 0.000 claims description 5
- 238000004898 kneading Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 241000131808 Scolopendra Species 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 58
- 239000008280 blood Substances 0.000 abstract description 58
- 210000002784 stomach Anatomy 0.000 abstract description 54
- 229940079593 drug Drugs 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 28
- 210000000952 spleen Anatomy 0.000 abstract description 28
- 238000005728 strengthening Methods 0.000 abstract description 9
- 238000012795 verification Methods 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 description 27
- 230000002829 reductive effect Effects 0.000 description 21
- 206010003694 Atrophy Diseases 0.000 description 18
- 230000037444 atrophy Effects 0.000 description 18
- 210000004400 mucous membrane Anatomy 0.000 description 18
- 210000001156 gastric mucosa Anatomy 0.000 description 16
- 210000004907 gland Anatomy 0.000 description 15
- 238000002203 pretreatment Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000004877 mucosa Anatomy 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 12
- 206010054949 Metaplasia Diseases 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 206010000087 Abdominal pain upper Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010000060 Abdominal distension Diseases 0.000 description 7
- 206010058314 Dysplasia Diseases 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- 230000005856 abnormality Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000000762 glandular Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000004206 stomach function Effects 0.000 description 6
- 206010067171 Regurgitation Diseases 0.000 description 5
- 208000032023 Signs and Symptoms Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 108010066264 gastrin 17 Proteins 0.000 description 5
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 description 5
- 230000015689 metaplastic ossification Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 206010015137 Eructation Diseases 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 206010041956 Stasis syndrome Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 208000005634 blind loop syndrome Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007873 sieving Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 206010014080 Ecchymosis Diseases 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 241001536563 Panus Species 0.000 description 3
- 108010047320 Pepsinogen A Proteins 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 206010016766 flatulence Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 238000002575 gastroscopy Methods 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000008728 vascular permeability Effects 0.000 description 3
- 206010016100 Faeces discoloured Diseases 0.000 description 2
- 108090001072 Gastricsin Proteins 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 240000001398 Typha domingensis Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000027687 belching Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101710198144 Endopolygalacturonase I Proteins 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 102000055441 Gastricsin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000264877 Hippospongia communis Species 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000034255 Pepsinogen C Human genes 0.000 description 1
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 description 1
- 241001038563 Pseudostellaria Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000002318 cardia Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000012856 weighed raw material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
Abstract
The invention discloses a compound traditional Chinese medicine for treating gastric precancerous lesions and a preparation method thereof, belonging to the technical field of medicines, wherein the compound traditional Chinese medicine comprises the following components: 5-15 parts of red sage root, 3-10 parts of fructus amomi, 6-12 parts of bighead atractylodes rhizome, 3-12 parts of rhizoma corydalis, 3-12 parts of magnolia officinalis, 3-15 parts of rhizoma curcumae, 3-10 parts of pollen typhae, 3-5 parts of centipede, 3-10 parts of honeycomb, 3-10 parts of spina gleditsiae, 9-30 parts of radix pseudostellariae, 15-60 parts of endothelium corneum gigeriae galli and 15-60 parts of oldenlandia diffusa. The compound traditional Chinese medicine disclosed by the invention is reasonable in compatibility, safe and effective, has the effects of removing blood stasis, dredging collaterals and strengthening spleen and stomach, and has an obvious curative effect through years of clinical verification; the preparation method of the invention has simple and practical operation, the dosage form prepared by the preparation method of the invention can be completely absorbed by the human body after being orally taken, has high bioavailability, and meanwhile, the watered pill, decoction and honeyed pill are easy to divide dosage, convenient to take, good in oral compliance, high in safety and obvious in curative effect.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a compound traditional Chinese medicine for treating gastric precancerous lesions and a preparation method thereof.
Background
The spleen and stomach are the acquired root, and are the source of qi and blood, and the internal injury to the spleen and stomach, the disease is caused by the generation of all diseases. The occurrence of chronic atrophic gastritis is closely related to weakness of spleen and stomach and dysfunction. When spleen and stomach are weakened and dysfunctions are caused, the food essence is generated, on the basis, qi and blood deficiency, viscera hypofunction, malnutrition of muscle tendons and vessels and long-term wither are caused. Moreover, the development of this disease is a chronic and prolonged process. It undergoes the transformation process of qi deficiency, qi stagnation, phlegm obstruction and blood stasis in the chance of disease, and undergoes the development process of chronic atrophic gastritis, intestinal metaplasia, abnormal hyperplasia and canceration in pathology. Wherein the formation of blood stasis is a key element of cancerous transformation of chronic atrophic gastritis. Blood stasis gives consideration to the dual identities of pathological products and pathogenic factors. Firstly, qi deficiency, qi stagnation and phlegm obstruction can lead to blood stasis. Conversely, stagnant blood aggravates the severity of qi deficiency, qi stagnation and phlegm obstruction. This forms a vicious circle, driving the disease toward severity and exacerbation. Therefore, the key to treat the precancerous lesions of chronic atrophic gastritis is to remove blood stasis and strengthen the spleen and stomach.
The existing compound traditional Chinese medicine technical proposal mostly treats the disease from the angles of regulating qi, strengthening the body resistance, eliminating damp evil and heat evil, and the like, and does not grasp the key pathogenesis of blood stasis, and does not achieve the compatibility of removing blood stasis and strengthening the body resistance. The traditional Chinese medicine is the reason that the existing technical scheme of the compound traditional Chinese medicine in the prior society has poor effect of treating the precancerous lesions of the chronic atrophic gastritis. In addition, the existing western medicine technical scheme mainly comprises regular follow-up and dietary structure improvement, and is matched with eradication of Hp, nonsteroidal drugs (NSAID), microelement supplementation, folic acid and the like, but the exact curative effect is uncertain. Therefore, the invention provides a compound traditional Chinese medicine for safely and effectively treating gastric precancerous lesions (Precancerous lesions ofgastric cancer, PLGC).
Disclosure of Invention
The invention aims to provide a compound traditional Chinese medicine for treating gastric precancerous lesions and a preparation method thereof, which solve the problems in the prior art, has reasonable compatibility, safety and effectiveness, and has obvious curative effect of strengthening spleen and stomach and strengthening body resistance and treating gastric precancerous lesions after years of clinical verification.
In order to achieve the above object, the present invention provides the following solutions:
The invention provides a compound traditional Chinese medicine for treating gastric precancerous lesions, which comprises the following raw materials in parts by weight: 5-15 parts of red sage root, 3-10 parts of fructus amomi, 6-12 parts of bighead atractylodes rhizome, 3-12 parts of rhizoma corydalis, 3-12 parts of magnolia officinalis, 3-15 parts of rhizoma curcumae, 3-10 parts of pollen typhae, 3-5 parts of centipede, 3-10 parts of honeycomb, 3-10 parts of spina gleditsiae, 9-30 parts of radix pseudostellariae, 15-60 parts of endothelium corneum gigeriae galli and 15-60 parts of oldenlandia diffusa.
Further, the compound traditional Chinese medicine comprises the following raw materials in parts by weight: 12 parts of red sage root, 10 parts of fructus amomi, 10 parts of bighead atractylodes rhizome, 12 parts of rhizoma corydalis, 12 parts of magnolia officinalis, 10 parts of rhizoma curcumae, 10 parts of pollen typhae, 4 parts of centipede, 10 parts of honeycomb, 10 parts of spina gleditsiae, 15 parts of radix pseudostellariae, 15 parts of endothelium corneum gigeriae galli and 15 parts of oldenlandia diffusa.
Further, the dosage forms of the compound traditional Chinese medicine comprise pills and decoction.
Further, the pill includes a water pill and a honey pill.
Further, the gastric precancerous lesions include gastric collateral stasis type chronic atrophic gastritis gastric precancerous lesions.
The invention also provides a preparation method of the compound traditional Chinese medicine, which comprises the following steps:
Pulverizing all the materials into powder, granulating by wet powder granulating and drawing method, spraying water to wet the powder particles, scattering powder for adsorption, repeating the operation to obtain uniform pill, and performing capping, drying and coating polishing treatment;
or pulverizing part of the materials into powder, granulating with wet powder granulating and demolding method, spraying the rest materials to obtain decoction, moistening, scattering powder, adsorbing, repeating the operation to obtain uniform pill, and finishing, drying, and coating and polishing.
Further, the partial raw materials comprise pollen typhae, centipede, honeycomb, chicken's gizzard-skin and spina gleditsiae; the decoction is prepared by decocting Saviae Miltiorrhizae radix, fructus Amomi, atractylodis rhizoma, rhizoma corydalis, cortex Magnolia officinalis, curcumae rhizoma, radix Pseudostellariae and herba Hedyotidis Diffusae with water.
The invention also provides a preparation method of the compound traditional Chinese medicine, which comprises the following steps:
mixing the weighed raw materials, soaking in water for 30-40 min, and decocting with strong fire for 40-50 min for the first time; decocting with water and slow fire for 30-40 min; decocting with water and slow fire for 20-30 min; mixing the medicinal liquids obtained from 3 times.
The invention also provides a preparation method of the compound traditional Chinese medicine, which comprises the following steps:
Weighing the raw materials, drying, pulverizing, mixing the obtained medicinal powder with the decocted Mel, concocting, mixing, kneading, and packaging.
Further, the mass ratio of the medicinal powder to the honey is 1: (1.2-1.5).
The invention discloses the following technical effects:
The compound Chinese medicine has the effects of promoting blood circulation, removing blood stasis, promoting qi circulation, relieving pain, removing blood stasis, eliminating mass, eliminating toxic materials, resolving hard mass, removing blood stasis, dredging collaterals, strengthening spleen, harmonizing stomach, eliminating dampness, promoting diuresis, supplementing qi, cultivating primordial qi and the like, has obvious therapeutic effect on precancerous lesions of gastric cancer, especially symptoms such as stomachache, gastrectasia, gastric acid, black stool and the like, and has high effective rate and no side effect. Bai Zhu in the recipe is warm in nature, bitter in taste and sweet in flavor, and has the actions of tonifying spleen and replenishing qi, drying dampness and promoting diuresis, so it is the first principal herb of spleen and tonifying qi. The "Ben Cao Tong Xuan" proposes "Bai Zhu, a medicine for nourishing spleen and stomach, but not the right one. It is also indicated for cases where it is not eaten because it can strengthen the body and transport due to excessive soil, and where it is stagnant. The excessive earth can dispel dampness, so it is also used for phlegm-fluid retention, edema and damp arthralgia. The excessive earth can cause clear qi to rise, while the essence is slightly upwards acting, turbid qi is well descending, and dregs are downwards transported, so vomiting and diarrhea can not be limited. This herb is sweet in taste and can tonify deficiency, bitter in taste and purgation excess, and plays an important role in treating this disease. The curcuma zedoary is pungent and bitter in flavor, warm in nature, enters liver and spleen meridians, and has the actions of promoting qi and breaking blood. Zhang Xichun the two drugs for the edge surgery are good at breaking blood, and are good at regulating qi … …, and can be used slowly, i.e. the person without blood stasis can use the circulation of the drugs to promote appetite by combining the drugs … … for tonifying the drugs with the drugs of Shen, zhu and Qi. ("formula for treating yin deficiency with consumptive fever & Shiquan Yuzhen Tang"), atractylodis rhizoma has the effects of invigorating spleen and stomach, curcumae rhizoma has the effects of breaking blood, eliminating mass, promoting qi circulation and relieving pain, both entering spleen meridian, acting as monarch drug, and invigorating spleen and activating blood. Dan Shen is bitter in flavor and can purgate, nourish blood and activate blood, and it is said that Dan Shen is the same herb as four things. Promoting blood circulation to remove blood stasis without hurting the healthy energy. Pu Huang has sweet nature and belongs to the two meridians of liver and pericardium, and has the actions of stopping bleeding and resolving stasis. The red sage root and the cattail pollen are good at activating blood and dissolving stasis, and the smile powder and the red sage root drink are combined, so the red sage root and the cattail pollen are used as ministerial drugs to assist in monarch. Magnolia officinalis is bitter and pungent and warm. Enter spleen, stomach, lung and large intestine meridians. It has the actions of drying dampness and resolving phlegm, descending qi and removing fullness, and dispersing spleen and stomach dampness. Yuan Hu Xin, bitter and warm, belongs to both meridians of liver and spleen, and qi stagnation in blood can smooth qi and regulate blood, which belongs to a good analgesic drug. The magnolia officinalis and the rhizoma corydalis play the role of regulating qi, and the rhizoma corydalis can promote blood circulation to remove blood stasis, promote qi circulation and relieve pain; hedyotidis Diffusae enters stomach, large intestine and small intestine meridians, has effects of clearing heat, detoxicating, relieving swelling, balancing nidus, and sweet in taste, entering stomach meridians, and has effects of removing toxic substances, killing parasites, dispelling pathogenic wind, and relieving pain. Modern researches have shown that the nidus Vespae has antibacterial, antitumor and antiinflammatory effects. For gastric cancer premalignant lesions and polyps with heat-toxin accumulation, phlegm-dampness retention and blood stasis and qi stagnation, it is indicated for the recipe of clearing heat, detoxicating, resolving dampness and activating blood circulation, and Hedyotidis Diffusae and nidus Vespae are used to directly break down the heat-toxin, so it can resolve phlegm-dampness and coagulate. The six medicines are all ministerial medicines. The spina gleditsiae has pungent and warm taste and enters liver, stomach and lung meridians, and can be used for benefiting thorns, relieving swelling, expelling pus, removing toxin and counteracting toxic substances; the centipede is pungent, warm and toxic, enters liver meridian, has the effects of dredging collaterals and relieving pain, and eliminating toxin and resolving masses, and is toxic in nature, and capable of dispersing swelling and removing blood stasis, so as to assist in detoxifying and dispersing swelling of oldenlandia diffusa and nidus vespae, and dredging collaterals and removing blood stasis; the chicken's gizzard-membrane is sweet in taste and neutral in nature, and belongs to spleen, stomach, small intestine and bladder meridian. Has effects in invigorating stomach, resolving food stagnation, and protecting spleen and stomach; fructus Amomi is pungent in flavor and warm in nature, enters spleen, stomach and kidney meridians, and has the actions of resolving dampness and promoting qi circulation, activating spleen and stimulating appetite. In clinic, the small dosage of fructus Amomi is used for treating various chronic gastropathy according to the physiological characteristics and pathological changes of the stomach, and is an essential drug for activating spleen and stomach. Chronic atrophic gastritis is due to deficiency of the long-term disease and blood stasis of gastric mucosa, so it is treated with Pseudostellaria root, radix Pseudostellariae, which has sweet and slightly bitter taste and is neutral in nature, enters both spleen and lung meridians. Replenishing qi to invigorate the spleen, tonifying qi and promoting the production of body fluid, the monarch drug can play the roles of invigorating spleen and replenishing qi. The five medicines are all adjuvant medicines. The whole prescription has mild medicinal taste and is aimed at removing blood stasis, dredging collaterals, strengthening spleen, reinforcing primordial qi, resolving hard mass, eliminating food retention and not hurting healthy energy.
The compound traditional Chinese medicine for treating gastric precancerous lesions provided by the invention has reasonable compatibility, safety and effectiveness, and has obvious curative effect on strengthening spleen and stomach and strengthening body resistance by being proved by clinical verification for many years. The preparation method of the invention is simple and practical to operate, the dosage form prepared by the preparation method of the compound preparation reduces the loss of active ingredients, the active ingredients can be completely absorbed by the human body after being orally taken, the bioavailability is high, and meanwhile, the water pill, the decoction and the honeyed pill are easy to be divided into dosage, convenient to take, good in oral compliance, high in safety and obvious in curative effect.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a flow chart of a preparation process of a water pill;
FIG. 2 is a flow chart of a process for preparing the modified watered pill;
FIG. 3 is a flow chart of a preparation process of the decoction;
FIG. 4 is a flow chart of the preparation process of the honeyed pill;
FIG. 5 is a gastroscopic report of a typical case patient prior to treatment;
FIG. 6 is a gastroscopic report of a typical case patient after treatment;
FIG. 7 is a pathology report of a typical case patient prior to treatment;
Fig. 8 is a pathology report after treatment of a typical case patient.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples of the present invention are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
The "Huangdi's Nei Jing" states that: "deep and prolonged disease is in nutrient Wei Zhihang astringent", sui Dynasty nest prescription is mentioned in "the disease Source and treatise on: "also distension and fullness due to obstruction of blood qi", the yenne is: the primary disease is in the meridian, and the chronic pain enters the collaterals to govern the qi and blood in the meridian. The invention considers that the stasis of stomach collaterals is the key pathogenesis of occurrence and development of chronic atrophic gastritis through the whole time of precancerous lesions.
The invention aims of the compound traditional Chinese medicine: mainly aims at forming gastric precancerous lesions which take blood stasis as a main pathogenesis and are caused by cementation of pathological factors such as qi stagnation or phlegm dampness, the gastric precancerous lesions refer to intestinal epithelial metaplasia and abnormal hyperplasia of gastric mucosa, chang Ji is caused by chronic atrophic gastritis, and the gastric precancerous lesions are easy to develop into gastric cancer. The compound is mainly suitable for gastric collateral stasis type chronic atrophic gastritis gastric precancerous lesions. Syndrome of stasis of stomach collaterals: main evidence: there is a constant feeling of fullness or pain in the stomach. Secondary symptoms: ① The stomach ache refuses to press; ② black stool; ③ Dark complexion. Tongue pulse: dark red tongue or ecchymosis; the pulse is wiry and astringent.
Example 1
A compound traditional Chinese medicine for treating gastric precancerous lesions consists of the following raw material medicines in parts by weight: 12 parts of red sage root, 10 parts of fructus amomi, 10 parts of bighead atractylodes rhizome, 12 parts of rhizoma corydalis, 12 parts of magnolia officinalis, 10 parts of rhizoma curcumae, 10 parts of pollen typhae, 4 parts of centipede, 10 parts of honeycomb, 10 parts of spina gleditsiae, 15 parts of radix pseudostellariae, 15 parts of endothelium corneum gigeriae galli and 15 parts of oldenlandia diffusa.
The preparation method of the watered pill comprises the following steps:
step 1, processing the raw materials according to requirements, crushing, sieving and mixing to obtain medicine fine powder for later use;
Step 2, stripping: the wet powder granulating and drawing process includes pelletizing the drawing medicine powder, rotating in a pan to eliminate edges, spraying water to wet, spraying powder to adsorb, repeating the process for several times, kneading, impacting, turning to form small spherical grains, sieving to eliminate oversized or undersized special shaped grains, and dissolving in water;
Step 3, calculating the pill die consumption: first, the weight of the powder (unit: g) for the present batch of pill-making was divided by 0.2 g (weight of one standard pellet), which is equivalent to how many standard pellets should be obtained. Weighing 5g of wet moulds by a balance, dividing 5g by the number to calculate the average weight of each pill mould, and multiplying the weight of each wet pill mould by the number of the standard water pills to obtain the quantity of the pill moulds;
Step 4, molding: alternately adding water and medicinal powder into the screened qualified pill mould, and gradually increasing to approach the final product. In the process, when the pill is large enough and is not easy to adhere, the water-soluble slurry of the preparation is sprayed on the prepared pill as an adhesive for use, and the pill cannot be discarded;
Step 5, pill selection: the pill is screened by a medicine screen to be uniform and consistent, the too small pill is enlarged again, and the oversized malformation should be separated out and dissolved in a proper amount of water for preparing the medicine, and the medicine is used as an adhesive for exhaustion. So that the finished products are uniform in size;
Step 6, capping: proper materials (clear water, clear slurry or fine powder of medicines) are widely manufactured on the qualified formed pellets to the size of finished products, so that the surfaces of the pellets are compact, smooth and consistent in color. The common capping methods include dry powder capping, clear water capping, clear slurry capping, etc., and the dry powder capping is adopted in the embodiment;
Step 7, drying: and (5) timely drying the capped pellets. The drying temperature is generally controlled below 80deg.C, and the pill containing volatile or heat-sensitive components should be dried below 60deg.C; gradually heating up during drying, and continuously turning over to prevent the pill from generating a sunny and shady surface; the drying temperature used in this example was 60 ℃;
Step 8, coating and polishing: moistening the dried watered pill with water, adding coating material, rotary coating, rotary polishing, and drying.
FIG. 1 is a flow chart of a preparation process of the watered pill.
Example 2
The preparation method of the improved watered pill comprises the following steps:
Step 1, weighing the raw materials in the embodiment 1, processing and passing the raw materials according to the requirements, and crushing, sieving and mixing part of the raw materials to prepare medicine fine powder for standby in order to facilitate the preparation and fully reserve the effective components in the prescription. The medicinal materials for preparing powder comprise pollen Typhae, scolopendra, nidus Vespae, endothelium corneum Gigeriae Galli and spina Gleditsiae.
The prescription contains a large amount of fiber and the active ingredients can be dissolved in water, and is designed to be prepared into decoction by adopting the traditional decoction method (refer to the preparation method of the embodiment 3) for standby. The medicinal juice is used as excipient. The decoction comprises Saviae Miltiorrhizae radix, fructus Amomi, atractylodis rhizoma, rhizoma corydalis, cortex Magnolia officinalis, curcumae rhizoma, radix Pseudostellariae and herba Hedyotidis Diffusae.
Step 2, stripping: the wet powder granulating and drawing process includes pelletizing the drawn medicine powder, rotating in a pan to eliminate edges, spraying medicine liquid for wetting, spraying medicine liquid for adsorbing, repeating the steps of kneading, impacting, turning, etc. to form small spherical grains, sieving to eliminate oversized or undersized special shaped grains and dissolving in medicine liquid;
Step 3, calculating the pill die consumption: first, the weight of the powder (unit: g) for the present batch of pill-making was divided by 0.2 g (weight of one standard pellet), which is equivalent to how many standard pellets should be obtained. Weighing 5g of wet moulds by a balance, dividing 5g by the number to calculate the average weight of each pill mould, and multiplying the weight of each wet pill mould by the number of the standard water pills to obtain the quantity of the pill moulds;
Step 4, molding: alternately adding the filtered pill mould into the medicinal juice and medicinal powder, and gradually increasing to approach the final product. In the process, when the pill is large enough and is not easy to adhere, the medicinal syrup water dissolved in the medicinal juice is used as an adhesive to be sprayed on the prepared pill, and the medicinal syrup water cannot be discarded;
Step 5, pill selection: the pill is screened by a medicine screen to be uniform and consistent, the too small pill is enlarged again, and the too large malformed should be separated out and dissolved in the medicine juice of the preparation to be used as the binder. So that the finished products are uniform in size;
step 6, capping: proper materials (medicinal liquid, medicinal slurry and fine powder of medicine) are widely applied to the qualified formed pellets until the size of the finished product is reached, so that the surfaces of the pellets are compact, smooth and consistent in color. Common capping methods include dry powder capping, liquid medicine capping, slurry capping, etc., and the dry powder capping is adopted in the embodiment;
Step 7, drying: and (5) timely drying the capped pellets. The drying temperature is generally controlled below 80deg.C, and the pill containing volatile or heat-sensitive components should be dried below 60deg.C; gradually heating up during drying, and continuously turning over to prevent the pill from generating a sunny and shady surface; the drying temperature used in this example was 60 ℃;
step 8, coating and polishing: the dried watered pill is moistened with water, added with coating material for rotary coating, and then rotary polishing is carried out to make the surface of the pill wet and glossy, and then the pill is taken out for drying.
FIG. 2 is a flow chart of the preparation process of the improved watered pill.
In the experiment, the clinical dosage of the improved watered pill is reduced to half of that of the traditional watered pill prepared in the embodiment 1, the compliance of patients is improved, the drug effect is improved, and the characteristics of masking the bad smell of the drug and convenient storage and administration are achieved.
Example 3
A compound traditional Chinese medicine for treating gastric precancerous lesions consists of the following raw material medicines in parts by weight: 10 parts of red sage root, 13 parts of fructus amomi, 6 parts of bighead atractylodes rhizome, 10 parts of rhizoma corydalis, 3 parts of magnolia officinalis, 15 parts of rhizoma curcumae, 3 parts of pollen typhae, 5 parts of centipede, 3 parts of honeycomb, 7 parts of spina gleditsiae, 9 parts of radix pseudostellariae, 60 parts of chicken's gizzard-skin and 20 parts of oldenlandia diffusa.
The preparation method of the decoction comprises the following steps:
weighing and mixing the raw materials according to the weight parts, adding 6 times of water according to the weight parts, soaking for 30 minutes, and decocting for 50 minutes by strong fire for the first time; adding water with the weight of 4 times of that of the second time, and decocting for 30 minutes with slow fire; decocting with 2 times of water with slow fire for 20 min; and combining the liquid medicine obtained in 3 times to obtain the compound traditional Chinese medicine decoction for treating gastric precancerous lesions.
Fig. 3 is a flow chart of a preparation process of the decoction.
Example 4
A compound traditional Chinese medicine for treating gastric precancerous lesions consists of the following raw material medicines in parts by weight: 5 parts of red sage root, 6 parts of fructus amomi, 12 parts of bighead atractylodes rhizome, 3 parts of rhizoma corydalis, 8 parts of magnolia officinalis, 3 parts of rhizoma curcumae, 7 parts of pollen typhae, 3 parts of centipede, 4 parts of honeycomb, 3 parts of spina gleditsiae, 30 parts of radix pseudostellariae, 15 parts of chicken's gizzard-skin and 60 parts of oldenlandia diffusa.
The preparation method of the honeyed pill comprises the following steps:
Weighing the raw materials according to parts by weight, baking with fine fire, and pulverizing into powder by a powder pulverizing machine, wherein the weight of the powder is 1:1.5, mixing honey, and decocting the honey; mixing refined bee with the medicinal powder, rubbing, mixing with pill, and packaging.
Fig. 4 is a flowchart of the preparation process of the honeyed pill.
Efficacy verification and observation of curative effect of stomach-harmonizing and stasis-resolving pill for treating stomach collateral stasis type PLGC
The watered pill preparation prepared in example 1 is called "stomach and blood stasis removing pill" (also called stomach and IV number).
1 Clinical data:
The source of the selected cases in the study is 2021, 6 to 2022, 9, the Western medicine diagnosis of the traditional Chinese medicine hospital in the autonomous region of inner Mongolia is PLGC, and 90 patients are outpatient department and inpatient department of the traditional Chinese medicine diagnosis of the stasis syndrome of stomach collateral.
2 Diagnostic criteria:
2.1 Western diagnostic criteria
Refer to the CAG diagnosis standard (trial run) of the medical science and diagnosis and treatment consensus opinion of the combination of the traditional Chinese medicine and the western medicine (2017) and the clinical research guidelines of new traditional Chinese medicines.
(1) Gastroscope diagnostic criteria:
① Mucosal color change: the mucosa color is grey white, grey yellow or grey when atrophy; the mucous membrane depth at the same position is inconsistent, the place with strong red is also provided with off-white, and the place with general off-yellow or off-white can be slightly raised with small red spots or red spots; the atrophy range can be diffuse, localized, focal, with the mucosa becoming thin and concave, and the boundaries often being insignificant.
② See-through of blood vessels: small blood vessels in the mucosa are visible in the early stage of atrophy, and dark red dendritic large blood vessels are visible in severe cases, and blood vessels of the fundus cardia are also visible under normal conditions.
③ After atrophy, the fossa glandular can proliferate and lengthen or intestinal epithelium grows, so that the formed mucous membrane layer becomes thick, at the moment, blood vessels under the mucous membrane can not be seen, the mucous membrane surface is rough and uneven, and particles or nodules are stiff.
(2) Pathological diagnosis criteria:
① Intrinsic glandular atrophy;
② Thickening of the mucosal layer;
③ Intestinal metaplasia or pseudo pyloroglandular metaplasia;
④ Intrinsic membrane inflammation;
⑤ Lymphoid follicular formation.
(3) Index standard of illness state
① Gastric mucosa gastroscope observation graduation standard
Light: the red and white phases are mainly white, and the vascular network is seen through and is often in a foci.
And (3) moderately: the red and white phases are mainly white, and the vascular network is obviously visible. Often diffuse, flattened and shallowed folds of the mucosa. Type B atrophy ranges from antrum to the upper and lower gastric angle levels.
Severe: in addition to the above manifestations, the mucous membrane is also formed into granules or nodules. Type B atrophy ranges to the middle upper part of the stomach.
② Glandular atrophy pathological histology degree standard
Light: intrinsic gland reduction is within 1/3;
and (3) moderately: the intrinsic glands are reduced by 1/3 to 2/3;
severe: the intrinsic glands are reduced by more than 2/3.
③ Pathological tissue degree standard of grading for intestinal epithelialization
Light: the intestinal surface epithelium and/or gland accounts for less than 1/3 of the total length of the mucous membrane;
and (3) moderately: the intestinal surface epithelium and/or gland accounts for 1/3-2/3 of the total length of the mucous membrane;
Severe: the intestinal surface epithelium and/or gland accounts for more than 2/3 of the total length of the mucous membrane.
④ Abnormal hyperplasia (atypical hyperplasia) pathological histology degree standard
Light: the cell nucleus is slightly large, deeply dyed, round, oval or columnar, is densely arranged and is positioned on the cell substrate. If the cell is stomach type, the epithelial cells are columnar, and mucous secretion is reduced; if the cells are intestinal, the goblet cells are reduced, and panus cells are rare. The gland tube is slightly proliferated, the tube cavity is slightly irregular, and the arrangement is slightly disordered and the density is uneven.
And (3) moderately: cell allotype is more obvious. The cell nucleus is enlarged, the oval or rod-shaped is different in size, dense in concentration, disordered in arrangement and uneven in dispersion, and has a pseudo-double-layer structure, and the nucleus is more divided. Epithelial cells are columnar, mucus secretion is obviously reduced, goblet cells are rare, and panus cells are not found. The gland tubes are densely arranged and have branch tortuosity, and the structures of the tube cavities are irregular and the shapes and the sizes are unequal.
Severe: cell atypical is very pronounced and sometimes indistinguishable from highly differentiated mucosal endothelial cancers. Epithelial cells are highly columnar (intestinal), and goblet cells and panus cells are absent; or in the form of a cube, an amorphous shape (stomach), the mucous secretion function disappears. The cell nucleus is obviously enlarged, the size and the shape are different, the arrangement is disordered, the irregularity is uneven, the nuclear/cell proportion is increased, the nucleus is concentrated or loose net-shaped, the nucleolus is obvious, and the division is common. The gland duct structure is obviously disordered, the shape, size and arrangement are extremely irregular, and the phenomena of budding, branching, nipple, common wall and back-to-back are common.
2.2 Diagnostic criteria for TCM
The diagnosis standard of the blood stasis syndrome of the stomach collaterals in the common medical knowledge of the combination of the traditional Chinese medicine and the western medicine for the chronic atrophic gastritis (2017) is referred.
The syndrome differentiation of Chinese medicine pertains to the stasis of the stomach collaterals, main symptoms are as follows: there is a constant feeling of fullness or pain in the stomach. Secondary symptoms: ① The stomach fullness or pain is not cured ② after a long time, and the stomach pain refuses to press or is painful like the dark complexion of the acupuncture ③. Tongue pulse: dark red tongue or ecchymosis; the pulse is wiry and astringent. The essential items in the above requirements are the main symptoms and tongue manifestations, the secondary symptoms are more than 1 item, and the diagnosis can be achieved by referring to the pulse manifestations.
3 Clinical case inclusion criteria and exclusion criteria:
3.1 inclusion criteria
(1) Ages between 18 and 72 years (including 18 and 72 years);
(2) Patients diagnosed with CAG via gastroscope, pathologically confirmed the presence of IM and/or Dys;
(3) The syndrome differentiation of Chinese medicine pertains to syndrome of stasis of stomach collaterals;
(4) Patients agree with each other, and the compliance is good, and the patients can voluntarily cooperate.
3.2 Exclusion criteria
(1) Serious primary diseases exist in important organs such as heart, lung, brain, liver, kidney and the like;
(2) Combining upper gastrointestinal hemorrhage;
(3) Taking non-steroidal anti-inflammatory drugs for a long time;
(4) Those suspected of having malignant lesions;
(5) Pregnant women and women in lactation period;
(6) Mental disorder such as depression, anxiety, etc. and poor fit of the person;
(7) Except for those with severe dysplasia.
3.3 Case rejection and shedding criteria
(1) The subjects can not comply with the use of the medicines, and can add medicines, subtract medicines, stop medicines or take medicines forbidden to the subject, so that the judgment of curative effect and safety is affected;
(2) The subject failed to adhere to the regular follow-up;
(3) The subject self-withdraws halfway.
3.4 Case suspension criteria
(1) During the test period the subject is unsuitable for continuing the test due to exacerbation;
(2) The subject is not suitable to continue the test and to receive special physiological changes due to complications.
3.5 Ethical examination and signing of informed consent and commitment
The whole study was in compliance with the declaration of helsinki, and all patients were required to learn about study methods and related precautions, and to sign informed consent and commitments, through review by the ethics committee, prior to treatment in the group.
4 Standard of efficacy
Is formulated by referring to the guidelines of clinical study of new Chinese medicine (trial).
4.1 Chinese medicine symptom curative effect evaluation criterion
① Clinical recovery: symptoms and signs disappear or disappear basically, and the integral of the symptoms is reduced by more than or equal to 95 percent;
② The effect is shown: the symptoms and signs are obviously improved, and the integral of the symptoms is reduced by more than or equal to 70 percent;
③ The method is effective: the symptoms and signs are improved, and the integral reduction of the symptoms is more than or equal to 30 percent;
④ Invalidation: the symptoms and signs are not obviously improved or even aggravated, and the integral of the symptoms is reduced by less than 30 percent.
Note that: the calculation formula (nimodipine method) is: [ (pre-treatment integral-post-treatment integral)/(pre-treatment integral ] ×100%
Total effective rate = (recovery + onset + efficacy)/(total number x 100%).
4.2 Evaluation of the efficacy of the Main symptoms of traditional Chinese medicine
① Clinical control: after the treatment course is finished, the symptoms disappear;
② The effect is shown: after the treatment course is finished, the symptoms are reduced by 2 grades in grades;
③ The method is effective: after the treatment course is finished, the symptoms are reduced by 1 grade in a grading way;
④ Invalidation: the above criteria are not met.
4.3 Gastroscope efficacy evaluation criteria
The endoscopic endoscope can be used for basically representing the white of mucous membrane with red and white color, the fold flattening and even disappearance, the exposed mucous membrane blood vessel, mucous membrane particles or nodules and the like. Referring to the diagnosis standard under CAG gastroscope in the "Chinese medicine New medicine clinical study guidelines" (trial), the color, blood vessel perspective, texture and the like of gastric mucosa are mainly observed under an endoscope, reasonable classification and grading quantification standards are formulated, and the curative effect comparison under the front and rear mirrors of treatment is carried out by applying an integration method.
4.4 Pathological efficacy evaluation criteria
① And (3) healing: histopathological examination confirmed that gland atrophy, intestinal epithelial metaplasia and dysplasia were restored to normal or disappeared.
② The effect is shown: histopathological examination confirmed that gland atrophy, intestinal metaplasia and dysplasia were restored to normal or reduced by 2 orders of magnitude.
③ The method is effective: histopathological examination confirmed that gland atrophy, intestinal epithelial metaplasia and dysplasia were reduced.
④ Invalidation: the above effective standard is not met, or worsened.
4.5 Evaluation of safety
1 Grade safety, no adverse reaction, no abnormality in safety index inspection;
The level 2 is safer, if adverse reaction occurs, the drug can be continuously administered without any treatment, and the safety index and the inspection have no abnormality;
The level 3 has the safety problem, moderate adverse reaction occurs, or the safety index is checked to have slight abnormality, and the administration can be continued after the treatment;
the level 4 aborts the test due to adverse reactions or the safety index checks for obvious anomalies.
5 Statistical method
All data entered Excel forms were then processed with SPSS25.0 and normal inspection was performed prior to processing. The counting data is checked by using a chi-square, the grade data is checked by using a non-parameter rank sum, the metering data is checked by using a t-test if the metering data accords with normal distribution, and the metering data does not accord with the normal distribution and is checked by using the non-parameter rank sum. If P <0.05, the difference is statistically significant.
Treatment regimen 6
6.1 Methods of treatment
96 Clinical patients with PLGC with stagnation of gastric collaterals meeting nanodischarge standard are randomly divided into 48 treatment groups (taking stomach and removing stasis pills) and control groups (taking stomach and recovering spring). The patients in the treatment group are administrated with the pill for treating stomach and removing blood stasis 3 times a day, 6g each time; patients in the control group took the Weifu chun capsules (produced by Hangzhou Hu Qingyu pharmaceutical Co., ltd., national drug standard Z20090697) 3 times daily, 4 granules each time. The treatment course is 6 months, and clinical observation and data statistical analysis are carried out.
6.2 Observations index
6.2.1 General index and safety Observation index
Each examination was performed 1 time before and at the end of the 6 th month of dosing. General indicators include pulse, respiration, blood pressure, cardiopulmonary auscultation, abdominal exam, etc.; the safety observation index content comprises blood routine, urine routine, stool routine + occult blood, liver function (ALT, AST), kidney function (BUN, cr) and electrocardiogram. And observing possible adverse reactions and detecting related indexes thereof, and reminding a patient to regularly review the related indexes and track the related indexes at any time if necessary.
6.2.2 Therapeutic Effect Observation index
(1) Gastroscopy
Each examination was performed 1 time before and at the end of the 6 th month of dosing. The color and luster of gastric mucosa, vascular permeability, mucosal texture and the like (see Table 1) are mainly observed by referring to the diagnosis standard under CAG gastroscope in the "Combined diagnosis and treatment consensus opinion of chronic atrophic gastritis (2017) and" clinical study guidelines of New Chinese medicine "(trial). And (3) injection: according to the normal orange color, the red-white phase and the white-red phase of the mucous membrane are respectively marked as 0, 1,2 and 3 points, the vascular permeability is no, the reticular and dendritic states are respectively marked as 0, 1 and 2 points, the fold of the mucous membrane is normal, less and vanished is respectively marked as 0, 1 and 2 points, the mucous membrane texture is smooth and soft, the mucous membrane is rough, and the granular change is respectively marked as 0, 1 and 2 points.
Table 1 evaluation of the mucosa under gastroscope
(2) Gastric mucosa pathohistological detection
Each examination was performed 1 time before and at the end of the 6 th month of dosing. The CAG disease index standard in the "chronic atrophic gastritis Chinese and Western medicine combined diagnosis and treatment consensus opinion" (2017) and "Chinese medicine New drug clinical research guidelines" is referred to. Changes in glandular atrophy, IM, dys were mainly observed, and were classified into four classes, none, light, medium, and heavy (see table 2). When taking materials, attention should be paid to the fact that the gastric mucosa tissue part taken at the end of the 6 th month of taking medicine is kept consistent with the material taking part before taking medicine as much as possible.
TABLE 2 evaluation of pathology
(3) Clinical symptoms
The main symptoms and signs are stomachache, fixed pain, distention and fullness in the stomach, refusal of pressing, anorexia, belch, acid regurgitation, dry mouth, bitter taste, nausea, emesis, dark complexion, unsmooth stool, dark red tongue or tongue with petechia and ecchymosis; wiry and astringent pulse. 1 time was recorded before taking medicine, at the end of 3 months and at the end of 6 months, and 3 times total. The grading quantification of the symptoms of the traditional Chinese medicine is carried out by referring to the guidelines of clinical research of new traditional Chinese medicines (trial). The main symptoms were marked as 0, 2,4 and 6 respectively, the sub-symptoms were marked as 0,1, 2 and 3 respectively, and the tongue pulse was not marked (see Table 3).
TABLE 3 integral manifestation of symptoms in TCM
(4) Gastric function detection
Each examination was performed 1 time before and at the end of the 6 th month of dosing. 4ml venous blood is extracted on an empty stomach and is sent to a laboratory for detection. Changes in pepsinogen I (Pepsinogen I, PG I), the ratio PGR of pepsinogen I to pepsin II (Pepsinogen II, PGII), and gastrin-17 (Gastrin, G-17) before and after treatment were observed.
6.2.3 Haemorheology
Before taking medicine and at the end of 6 th month, 1 time of examination is carried out, 4ml of venous blood is extracted on an empty stomach, and the blood is sent to an examination department for examination.
7. Therapeutic results
90 Patients are tested according to the requirement, 45 patients in the treatment group and the control group are treated by statistics, and the baseline data of gender, age, disease course and the like before treatment of the two groups of patients are basically the same, and the patients have comparability (P is more than 0.05).
7.1 Total effective rate of clinical symptoms
After 6 months of administration, the treatment group heals 2 cases, 16 cases are obvious in effect, 24 cases are effective, 3 cases are ineffective, and the effective rate is 93.33%; the control group heals 0 cases, has 1 case of obvious effect, 34 cases of effective effect, 10 cases of ineffective effect, and the effective rate is 77.78% (see table 4).
TABLE 4 Total effective rate of stomach-harmonizing and stasis-resolving pill on clinical symptoms
The total effective rate of the symptoms of the treatment group is 93.33% by the test of the chi-square, the control group is 77.78%, and the difference has statistical significance (P < 0.05).
7.2 Integration of symptoms of TCM before and after treatment
Table 5 integration of the symptoms of the Chinese medicine before and after the treatment of the pills for regulating stomach and removing blood stasis
Note that: the data is denoted as M (P 25,P75). Post-treatment versus pre-treatment * P <0.05 for the treatment group, and pre-treatment versus ▲ P <0.05 for the control group.
7.3 Integral distribution of gastric mucosa of patients before and after treatment
TABLE 6 integral distribution of gastric mucosa of patients before and after treatment with pills for regulating stomach and removing blood stasis
Note that: post-treatment versus pre-treatment * P <0.05 for the treatment group, and pre-treatment versus ▲ P <0.05 for the control group.
Compared with the control group, the pretreatment group has no statistical significance (P > 0.05) on the differences of the distribution conditions of the mucosa color, vascular permeability, mucosa fold and mucosa texture score of the patient, and has comparability. The number of people in each group is increased by 0 minute and 1 minute compared with the color of the mucous membrane before treatment, and the number of people in each group is reduced by 2 minutes and 3 minutes; the number of 0 parts of blood vessels is increased, the number of 1 part of mucosa folds and mucosa tissue is decreased, and the differences are statistically significant (P < 0.05). The distribution of the scores of the two groups of mucous membrane colors and mucous membrane textures after treatment shows that the severity of the treatment group is lighter than that of the control group, and the difference has statistical significance (P < 0.05); the difference of score distribution of vascular clear and mucosa fold has no statistical significance (P > 0.05).
7.4 Pathological tissue classification of gastric mucosa before and after treatment
TABLE 7 influence of stomach and stasis dispelling pills on gastric mucosa pathological grading of patients before and after treatment
Note that: post-treatment versus pre-treatment * P <0.05 for the treatment group, and pre-treatment versus ▲ P <0.05 for the control group.
Compared with the control group, the pre-treatment group has no statistical significance (P > 0.05) on the difference of gastric mucosa gland atrophy, intestinal epithelial metaplasia (IM) and dysplasia (Dys) of the patients, and has comparability. The severity of the two groups was improved in terms of glandular atrophy and IM (P < 0.05) compared to the post-treatment versus pre-treatment, and differences in terms of Dys were not statistically significant (P > 0.05). The difference between IM grading conditions of the two groups after treatment is statistically significant (P < 0.05), and the difference between glandular atrophy and dysgrading conditions is not statistically significant (P > 0.05).
7.5 Detection results of gastric function before and after treatment
Table 8 gastric function test results of patients before and after treatment with pills for regulating stomach function and removing blood stasis
Note that: post-treatment versus pre-treatment * P <0.05 for the treatment group, and pre-treatment versus ▲ P <0.05 for the control group.
The difference in PGI, PGR, G-17 levels between the two groups of patients prior to treatment was not statistically significant (P > 0.05). PGI and PGR levels were increased after treatment and G-17 levels were decreased before treatment, and the difference was statistically significant (P < 0.05). The post-treatment group had higher PGI and PGR levels, and lower G-17 levels (P < 0.05) compared to the control group, and the differences were statistically significant.
7.6 Results of haemorheology tests
TABLE 9 results of hemorheological measurements of pills for treating gastric diseases and stasis in patients before and after treatment
Note that: post-treatment versus pre-treatment * P <0.05 for the treatment group, and pre-treatment versus ▲ P <0.05 for the control group.
The two groups of whole blood with low shear rate, high shear rate, plasma viscosity, reduced viscosity (low), reduced viscosity (high), erythrocyte aggregation index, erythrocyte rigidity index and fibrinogen level difference before treatment have no statistical significance (P > 0.05), and are comparable. The two groups of whole blood after treatment had low shear rate, high shear rate, plasma viscosity, reduced viscosity (low), reduced viscosity (high), erythrocyte aggregation index, erythrocyte rigidity index, fibrinogen was on average lower than before treatment (P < 0.05). The treated group had lower shear rates of whole blood, higher shear rates of whole blood, plasma viscosity, reduced viscosity of whole blood (low), reduced viscosity of whole blood (high), red blood cell aggregation index, red blood cell rigidity index, fibrinogen levels lower than the control group, and the differences were statistically significant (P < 0.05).
7.7 Safety index detection Condition
After two groups of treatment, blood convention, liver function, kidney function and stool convention are added with occult blood, urine convention and electrocardiogram have no abnormality related to medication, and the safety standard is met.
Conclusion 7.8
The pill for regulating stomach and removing blood stasis can effectively relieve symptoms of gastric collateral stasis syndrome of gastric precancerous lesions, improve the condition of endoscopic gastric mucosa, block and even reverse pathological changes of gastric mucosa and regulate gastric functions. The mechanism is probably due to the effects of improving hemorheology, reducing blood viscosity and treating gastric precancerous lesions. The clinical application of the medicine has safety.
Typical cases:
a first visit by men, 71 years, 7 months and 06 days 2022.
Patients complain about me with "bloating, belching for 6 years, aggravating stomach ache for 5 days". The current medical history: no obvious causes of gastric distention, eructation, occasional acid regurgitation and heartburn occur before 6 years, and the intermittent taking of the Chinese medicinal decoction improves the stomach recovery. No obvious causes of gastric distention and eructation aggravate before 5 days, and the gastralgia appears, and the self-administration of the traditional Chinese medicine can not be relieved, so that the patient can visit the hospital. The symptoms are as follows: stomach distention, belch, stink and tenderness in the stomach, acid regurgitation, heart burning, palpitation, excessive flatulence, anorexia, insomnia, urination, constipation, dry stool for 3 days and 1 row. A dark red tongue with thin and white coating and a thready and astringent pulse. Gastroscopy cues: reflux esophagitis (LA-A), chronic atrophic gastritis; pathological prompt: moderate atrophy of gastric sinus mucosa, severe intestinal metaplasia, partial gland mild moderate dysplasia, gastric mucosa mild atrophy, mild intestinal metaplasia and little gland mild dysplasia. Hp negative. The gastroscopic report of the patient before treatment is shown in fig. 5, and the pathological report before treatment is shown in fig. 7. The diagnosis of the traditional Chinese medicine and the western medicine accords with the PLGC stomach collateral blood stasis syndrome, the examination of general indexes and safety indexes does not have obvious abnormality, the group entering requirement is met, the group entering requirement is selected as a treatment group through a random digital table method, and the examination is carried out after taking the stomach and blood stasis removing pill for 6 months.
Two diagnoses (2022, 10, 24 days): after 3 months of administration, the patient has obvious relief of spontaneous gastrectasia, belch, relief of gastralgia and refusal of pressure degree in pain parts, occasional acid regurgitation, heartburn, no palpitation, reduced flatulence, anorexia, dreaminess, urination, dry stool for 1 day and 1 line. A pale-dark red tongue with thin and white coating, and a deep, thready and wiry pulse. The pill for regulating stomach and removing blood stasis is taken continuously for 3 months and then is reviewed.
Three diagnoses (2023, 2, 17 days): the patient takes the medicine for 6 months, and the stomach distention, the gastralgia, the occasional belching, the acid regurgitation and the heart burning are eliminated, and the patient is normal in the state of the flatulence, the anorexia, the general sleep and the urination and defecation are regulated. A red tongue with thin and white coating and a thready and wiry pulse. Gastroscope prompting: gastroscopy cues: reflux esophagitis (LA-A), chronic atrophic gastritis; pathological results: stomach Dou Bu presents with mild atrophy, mild intestinal metaplasia, and gastric mucosa presents with mild chronic inflammation. Hp negative. There is no obvious abnormality in the general index and the safety index review. The gastroscopic report of the patient after treatment is shown in fig. 6, and the pathological report after treatment is shown in fig. 8.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (7)
1. The compound traditional Chinese medicine for treating the gastric precancerous lesions is characterized by comprising the following raw materials in parts by weight: 5-15 parts of red sage root, 3-10 parts of fructus amomi, 6-12 parts of bighead atractylodes rhizome, 3-12 parts of rhizoma corydalis, 3-12 parts of magnolia officinalis, 3-15 parts of rhizoma curcumae, 3-10 parts of pollen typhae, 3-5 parts of centipede, 3-10 parts of honeycomb, 3-10 parts of spina gleditsiae, 9-30 parts of radix pseudostellariae, 15-60 parts of endothelium corneum gigeriae galli and 15-60 parts of oldenlandia diffusa;
the compound traditional Chinese medicine is in the form of pills; the gastric precancerous lesion is gastric collateral stasis type chronic atrophic gastritis gastric precancerous lesion.
2. The compound traditional Chinese medicine according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 12 parts of red sage root, 10 parts of fructus amomi, 10 parts of bighead atractylodes rhizome, 12 parts of rhizoma corydalis, 12 parts of magnolia officinalis, 10 parts of rhizoma curcumae, 10 parts of pollen typhae, 4 parts of centipede, 10 parts of honeycomb, 10 parts of spina gleditsiae, 15 parts of radix pseudostellariae, 15 parts of endothelium corneum gigeriae galli and 15 parts of oldenlandia diffusa.
3. The compound traditional Chinese medicine according to claim 1, wherein the pill is a watered pill or a honeyed pill.
4. The method for preparing the compound traditional Chinese medicine according to claim 1, which is characterized by comprising the following steps:
Pulverizing all the materials into powder, granulating by wet powder granulating and drawing method, spraying water to wet the powder particles, scattering powder for adsorption, repeating the operation to obtain uniform pill, and performing capping, drying and coating polishing treatment;
or pulverizing part of the materials into powder, granulating with wet powder granulating and demolding method, spraying the rest materials to obtain decoction, moistening, scattering powder, adsorbing, repeating the operation to obtain uniform pill, and finishing, drying, and coating and polishing.
5. The method according to claim 4, wherein the partial raw materials include pollen Typhae, scolopendra, nidus Vespae, endothelium corneum Gigeriae Galli, and spina Gleditsiae; the decoction is prepared by decocting Saviae Miltiorrhizae radix, fructus Amomi, atractylodis rhizoma, rhizoma corydalis, cortex Magnolia officinalis, curcumae rhizoma, radix Pseudostellariae and herba Hedyotidis Diffusae with water.
6. The method for preparing the compound traditional Chinese medicine according to claim 1, which is characterized by comprising the following steps:
Weighing the raw materials, drying, pulverizing, mixing the obtained medicinal powder with the decocted Mel, concocting, mixing, kneading, and packaging.
7. The method according to claim 6, wherein the mass ratio of the powder to the honey is 1: (1.2-1.5).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311237212.7A CN117045762B (en) | 2023-09-22 | Compound traditional Chinese medicine for treating gastric precancerous lesions and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311237212.7A CN117045762B (en) | 2023-09-22 | Compound traditional Chinese medicine for treating gastric precancerous lesions and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117045762A CN117045762A (en) | 2023-11-14 |
| CN117045762B true CN117045762B (en) | 2024-11-15 |
Family
ID=
Non-Patent Citations (1)
| Title |
|---|
| 胃和化瘀丸治疗胃癌前病变胃络愚瘀阻证的疗效与作用机制研究;马颖聪，等;内蒙古医科大学学报;20240430;第46卷(第02期);第134-139页 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100518807C (en) | A Medicine for treatment of ascites due to cirrhosis | |
| CN101961480A (en) | Traditional Chinese medicinal composition for treating hematochezia and preparation method thereof | |
| CN103585514A (en) | Traditional Chinese medicine composition for treating stomach cancer, application and preparation | |
| CN101953936B (en) | Traditional Chinese medicine preparation for treating immune thrombocytopenia and preparation method thereof | |
| CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
| CN108853258B (en) | Traditional Chinese medicine composition for treating functional constipation and application thereof | |
| CN107375815A (en) | A kind of Chinese medicine for treating tumor in digestive tract | |
| CN100509034C (en) | Medicine for treating chronic atrophic gastritis | |
| CN104398733B (en) | A kind of Chinese medicine preparation for treating caused by hepatic stagnation qi stagnation thyroid cancer | |
| CN117045762B (en) | Compound traditional Chinese medicine for treating gastric precancerous lesions and preparation method | |
| CN105497864A (en) | Drug for treating epistaxis and preparation method | |
| CN102205068B (en) | Medicament for treating chronic ulcerative colitis and preparation method thereof | |
| CN104258263A (en) | Chinese herba preparation for treating stomach-yin deficiency type chronic atrophic gastritis | |
| CN104436048A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating qi stagnation and blood stasis type chloasma | |
| CN117045762A (en) | Compound traditional Chinese medicine for treating gastric precancerous lesions and preparation method | |
| CN116808110B (en) | Intestine-moistening and bowel-relaxing formula and preparation method thereof | |
| CN116059302B (en) | Traditional Chinese medicine composition for treating gastrointestinal motility diseases and preparation method and application thereof | |
| CN104352717A (en) | Traditional Chinese medicine preparation for treating spleen-qi weakness type hemafecia and preparation method thereof | |
| CN104399040A (en) | Drug for treating gastrectasia and preparation method thereof | |
| CN113855778B (en) | Traditional Chinese medicine for treating spleen-kidney yang deficiency obstinate phlegm blood type esophageal cancer | |
| CN110051812A (en) | A kind of strengthening vital QI to eliminate pathogenic factors Chinese medicine and preparation method thereof | |
| CN113304234B (en) | Traditional Chinese medicine composition for treating chronic renal failure | |
| CN114732889B (en) | Traditional Chinese medicine composition and traditional Chinese medicine oral preparation for treating phlegm turbidity and lung obstruction in acute attack stage of bronchial asthma | |
| CN101757285B (en) | Gastrointestinal disease-treating traditional Chinese medicine composition containing costustoot and preparation method thereof | |
| CN105943860A (en) | Medicine preparation for treating diabetes mellitus and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |